Arsenieva Diana, Appavu Brian L, Mazock Gloria H, Jeffery Constance J
Laboratory for Molecular Biology, Department of Biological Sciences, University of Illinois, Chicago, Illinois 60607, USA.
Proteins. 2009 Jan;74(1):72-80. doi: 10.1002/prot.22133.
Enzymes of glycolysis in Trypanosoma brucei have been identified as potential drug targets for African sleeping sickness because glycolysis is the only source of ATP for the bloodstream form of this parasite. Several inhibitors were previously reported to bind preferentially to trypanosomal phosphoglucose isomerase (PGI, the second enzyme in glycolysis) than to mammalian PGIs, which suggests that PGI might make a good target for species-specific drug design. Herein, we report recombinant expression, purification, crystallization and X-ray crystal structure determination of T. brucei PGI. One structure solved at 1.6 A resolution contains a substrate, D-glucose-6-phosphate, in an extended conformation in the active site. A second structure solved at 1.9 A resolution contains a citrate molecule in the active site. The structures are compared with the crystal structures of PGI from humans and from Leishmania mexicana. The availability of recombinant tPGI and its first high-resolution crystal structures are initial steps in considering this enzyme as a potential drug target.
布氏锥虫糖酵解途径中的酶已被确定为治疗非洲昏睡病的潜在药物靶点,因为糖酵解是这种寄生虫血液形式唯一的ATP来源。此前有报道称,几种抑制剂优先与锥虫磷酸葡萄糖异构酶(PGI,糖酵解途径中的第二种酶)结合,而不是与哺乳动物的PGI结合,这表明PGI可能是物种特异性药物设计的良好靶点。在此,我们报告了布氏锥虫PGI的重组表达、纯化、结晶及X射线晶体结构测定。在1.6埃分辨率下解析的一个结构在活性位点含有处于伸展构象的底物D-葡萄糖-6-磷酸。在1.9埃分辨率下解析的第二个结构在活性位点含有一个柠檬酸盐分子。将这些结构与来自人类和墨西哥利什曼原虫的PGI晶体结构进行了比较。重组布氏锥虫PGI的可得性及其首个高分辨率晶体结构是将该酶视为潜在药物靶点的初步步骤。